Phase 3 randomized double-blind placebo-controlled trial of nemolizumab in adults with prurigo nodularis

Phase 3, randomised, double-blind trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Primary endpoints: Proportion of subjects with at least 4-point improvement from baseline in Peak Pruritus Numeric Rating Scale at Week 16 and Proportion of subjects with Investigator Global Assessment success at Week 16. Started Jul 2021; status: completed.